Topic 3: What is Necessary to Interpret Epigenetics in Light of Reprotoxicity Studies?
Moderator: Roland Buesen
Rapporteur: Kamin Johnson
The following needs were identified – and independent of the chosen model:
Bioinformatics: This technique is required and should be developed. Training will be required: for staff preparing the samples, and for data interpretation. Processes to share results (e.g. publications) and the transfer of data should be agreed up front.
Defining normality for the epigenetic endpoint(s): Including normality at the time of analysis and normality within the system (tissue, cell, etc). Chemical companies could be asked to provide both control and experimental samples from ongoing technical guideline studies and in-house work in order to support this work.
Functional linkage of the epigenetic endpoint to the apical (adverse) endpoint: This can potentially be used in the AOP framework.
Dose response especially with regard to Risk Assessment and No-effect level.
Inheritance of the epigenetic change: Is the effect transient or persistent across lifetime? Is the epigenetic change seen in the germline? Is the compound metabolism in the model similar to the human? (Which model is relevant to interpret data when we think about risk assessment for humans?)
Model? In utero exposure with postnatal examination? Do we have an influence on susceptibility to additional stressors – and can this be measured?